Alloimmune hepatitis following peripheral stem cell transplantation.
Habib
S
S
Nalesnik
M A
MA
Ahmad
J
J
BuchBarker
D
D
Shakil
A O
AO
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001379:Azathioprine / Q000008:administration & dosage; D002066:Busulfan / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D019693:Hepatitis, Autoimmune / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000150:complications* / Q000628:therapy; D019653:Myeloablative Agonists / Q000008:administration & dosage; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D011241:Prednisone / Q000008:administration & dosage; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists; D003520:Cyclophosphamide; D002066:Busulfan; D001379:Azathioprine; D011241:Prednisone